February 15, 2022

The University of Cincinnati is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications. ACTIV-6, “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” is a nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States through its website.

November 17, 2022

According to a report in early 2022 from the Centers for Disease Control and Prevention, more than 37 million people in the United States have diabetes, which is more than 11% of the population. Diabetes was the seventh leading cause of death in the United States in 2017 based on the death certificates in which diabetes was listed as the underlying cause of death. A newly launched University of Cincinnati partnership is aiming to put a dent in those numbers in Greater Cincinnati.

February 22, 2021

Shaina Horner, a clinical researcher in the Division of Infectious Diseases used her connections in the local Latinx community to help recruit a diverse population for the Moderna COVID-19 vaccine trial.